Isoxicam

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Isoxicam
Isoxicam skeletal V1.svg
Clinical data
Trade namesMaxicam
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.047.334 Edit this at Wikidata
Chemical and physical data
FormulaC14H13N3O5S
Molar mass335.34 g/mol g·mol−1
3D model (JSmol)

Isoxicam is a nonsteroidal anti-inflammatory drug (NSAID) that was taken or applied to reduce inflammation and as an analgesic reducing pain in certain conditions. The drug was introduced in 1983 by the Warner-Lambert Company. Isoxicam is a chemical analog of piroxicam (Feldene) which has a pyridine ring in lieu of an isoxazole ring. In 1985 Isoxicam was withdrawn from the French market, due to adverse effects, namely Toxic Epidermal Necrolysis (Lyell syndrome) resulting in death. Although these serious side effects were observed only in France, the drug was withdrawn worldwide.[1][2]

References[edit]

  1. ^ Consolidated List of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by Governments, United Nations, 2003, p. 123 link to 2005 ed
  2. ^ Fung, M.; Thornton, A.; Mybeck, K.; Wu, J. H.-h.; Hornbuckle, K.; Muniz, E. (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134.